Glaucoma changes rapid contrast adaptation

Article

Glaucoma, but not ageing, changes rapid contrast adaptation, which is vital to visual processing in natural visual environments, say researchers from Australia in a recent study.

Glaucoma, but not ageing, changes rapid contrast adaptation, which is vital to visual processing in natural visual environments, say researchers from Australia in a recent study. "Our results imply that glaucoma produces abnormalities in natural visual experiences in central vision," they write.

Their study included 14 people with glaucoma, 17 age-similar controls, and 19 younger adults. The investigators measured contrast detection and discrimination thresholds in central vision for briefly presented Gabor patches with and without adaptation to 50% contrast Gabor patches. They measured detection thresholds at 47, 106, 200, 400, 600 and 1000 msecs adaptation, and they measured discrimination thresholds after adaptation relative to a reference contrast below, equivalent to, or above the adaptor.

The unadapted detection and discrimination thresholds were elevated in those in the glaucoma group compared with the age-similar controls, the authors found. Ageing elevated unadapted thresholds in normal observers. At 47 msecs after adaptation, those in the glaucoma group experienced reduced effects of adaptation relative to those in the control group. Adaptation was also reduced when the reference contrast was equivalent to the adaptor. Ageing, however, did not change adaptation in normal observers.

To read an abstract of the study, visit the journal

Investigative Ophthalmology and Visual Science

.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.